Genitope Pulls Plug On Cancer Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants another Phase III trial with non-Hodgkins lymphoma drug.
You may also be interested in...
Favrille Ends Specifid Follicular B-Cell NHL Vaccine Program After Phase III Failure
Specifid is the second vaccine candidate for follicular non-Hodgkin’s lymphoma to fail this year, following Genitope’s MyVax results in March.
Favrille Ends Specifid Follicular B-Cell NHL Vaccine Program After Phase III Failure
Specifid is the second vaccine candidate for follicular non-Hodgkin’s lymphoma to fail this year, following Genitope’s MyVax results in March.
Failed MyVax Cancer Vaccine Trial Could Be Due To Active Comparator, Genitope Says
Firm remains optimistic about the non-Hodgkin’s lymphoma vaccine due to a statistically significant increase in progression-free survival among MyVax responders.